
We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Breaking News
CARB-X Receives Additional $370m from U.S. Government and Wellcome
May 25, 2022
Enables continued investment in innovative projects to tackle the growing global threat posed by AMR
Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
May 16, 2022
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022
Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism
April 12, 2022
Infex Therapeutics, one of the UK’s leading infectious disease biotech companies, has today lauded the conclusions of a NHS England and the National Institute for Health and Care Excellence (NICE)…
Latest News
Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
May 16, 2022
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022
Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism
April 12, 2022
Infex Therapeutics, one of the UK’s leading infectious disease biotech companies, has…
Infex scientists achieve breakthrough to overcome critical priority drug resistant infections
March 11, 2022
One of the UK’s leading infectious disease biotech companies has announced a breakthrough…
Infex agrees partnership with Colibri Scientific to provide services for RESP-X program
December 13, 2021
Infex Therapeutics has today announced a deal with Colibri Scientific, to provide…
Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
December 2, 2021
One of the UK’s leading infectious disease biotech companies has announced a breakthrough…
Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics
November 1, 2021
“The announcement today that the government is increasing public R&D investment to record…
Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership
July 29, 2021
Infex Therapeutics is pressing ahead with a major development of its pandemic resilience…
Tackling underlying respiratory conditions for this pandemic and next
July 6, 2021
During the COVID-19 pandemic, one of the many phrases that has become irreversibly etched…
Infex partners with Alderley Analytical to provide PK and ADA analysis for RESP-X program
May 25, 2021
Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and…
Sign up complete!
×Thank you for signing up to The AMR Centre’s mailing list which will ensure a timely flow of information and news.